APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

VEGF Antibody

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global VEGF Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174045630331 December 2025199 pages

Choose your research edition.

Industry ResearchVEGF Antibody Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal VEGF Antibody Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal VEGF Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal VEGF Antibody Market Outlook and Growth Opportunities 2026214 pages · $4,250 USDMarket Analysis & ForecastGlobal VEGF Antibody Market Analysis and Forecast 2026-2032214 pages · $4,950 USD

Market perspective

The global VEGF Antibody market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for VEGF Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for VEGF Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for VEGF Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for VEGF Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of VEGF Antibody include Abcam, Abnova, Absolute Antibody, Agrisera, BioLegend, Bio-Rad, Bon Opus Biosciences, Creative Biomart and Enzo Life Sciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global VEGF Antibody market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of VEGF Antibody and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents VEGF Antibody sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the VEGF Antibody market size, projected growth trends, production technologies, key applications, and end-use industries.

VEGF Antibody Segment by Company

Abcam

Abnova

Absolute Antibody

Agrisera

BioLegend

Bio-Rad

Bon Opus Biosciences

Creative Biomart

Enzo Life Sciences

ImmunoStar

LifeSpan Biosciences

MilliporeSigma

Novus Biologicals

OriGene

ProMab

R&D Systems

Rockland Immunochemicals

Santa Cruz Biotechnology

Sino Biological

US Biological

Boster

Thermo Fisher

VEGF Antibody Segment by Type

Rabbit

Mouse

Goat

Others

VEGF Antibody Segment by Application

Laboratory

Hospital

Others

VEGF Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global VEGF Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of VEGF Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of VEGF Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the VEGF Antibody market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of VEGF Antibody manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of VEGF Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of VEGF Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. VEGF Antibody Industry Trends Table 2. VEGF Antibody Industry Drivers Table 3. VEGF Antibody Industry Opportunities and Challenges Table 4. VEGF Antibody Industry Restraints Table 5. Global VEGF Antibody Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global VEGF Antibody Revenue Market Share by Manufacturers (2021-2026) Table 7. Global VEGF Antibody Sales by Manufacturers (Kg) & (2021-2026) Table 8. Global VEGF Antibody Sales Market Share by Manufacturers Table 9. Global VEGF Antibody Average Sales Price (US$/g) of Manufacturers (2021-2026) Table 10. Global VEGF Antibody Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global VEGF Antibody Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global VEGF Antibody Manufacturers, Product Type & Application Table 13. Global VEGF Antibody Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global VEGF Antibody by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Rabbit Table 17. Major Manufacturers of Mouse Table 18. Major Manufacturers of Goat Table 19. Major Manufacturers of Others Table 20. Global VEGF Antibody Sales by Type 2021 VS 2025 VS 2032 (Kg) Table 21. Global VEGF Antibody Sales by Type (2021-2026) & (Kg) Table 22. Global VEGF Antibody Sales by Type (2027-2032) & (Kg) Table 23. Global VEGF Antibody Sales Market Share by Type (2021-2026) Table 24. Global VEGF Antibody Sales Market Share by Type (2027-2032) Table 25. Global VEGF Antibody Revenue by Type 2021 VS 2025 VS 2032 (Kg) Table 26. Global VEGF Antibody Revenue by Type (2021-2026) & (Kg) Table 27. Global VEGF Antibody Revenue by Type (2027-2032) & (Kg) Table 28. Global VEGF Antibody Revenue Market Share by Type (2021-2026) Table 29. Global VEGF Antibody Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Laboratory Table 31. Major Manufacturers of Hospital Table 32. Major Manufacturers of Others Table 33. Global VEGF Antibody Sales by Application 2021 VS 2025 VS 2032 (Kg) Table 34. Global VEGF Antibody Sales by Application (2021-2026) & (Kg) Table 35. Global VEGF Antibody Sales by Application (2027-2032) & (Kg) Table 36. Global VEGF Antibody Sales Market Share by Application (2021-2026) Table 37. Global VEGF Antibody Sales Market Share by Application (2027-2032) Table 38. Global VEGF Antibody Revenue by Application 2021 VS 2025 VS 2032 (Kg) Table 39. Global VEGF Antibody Revenue by Application (2021-2026) & (Kg) Table 40. Global VEGF Antibody Revenue by Application (2027-2032) & (Kg) Table 41. Global VEGF Antibody Revenue Market Share by Application (2021-2026) Table 42. Global VEGF Antibody Revenue Market Share by Application (2027-2032) Table 43. Global VEGF Antibody Sales by Region: 2021 VS 2025 VS 2032 (Kg) Table 44. Global VEGF Antibody Sales by Region (2021-2026) & (Kg) Table 45. Global VEGF Antibody Sales Market Share by Region (2021-2026) Table 46. Global VEGF Antibody Sales Forecasted by Region (2027-2032) & (Kg) Table 47. Global VEGF Antibody Sales Forecasted Market Share by Region (2027-2032) Table 48. North America VEGF Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Kg) Table 49. North America VEGF Antibody Sales by Country (2021-2026) & (Kg) Table 50. North America VEGF Antibody Sales by Country (2027-2032) & (Kg) Table 51. Europe VEGF Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Kg) Table 52. Europe VEGF Antibody Sales by Country (2021-2026) & (Kg) Table 53. Europe VEGF Antibody Sales by Country (2027-2032) & (Kg) Table 54. Asia Pacific VEGF Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Kg) Table 55. Asia Pacific VEGF Antibody Sales by Country (2021-2026) & (Kg) Table 56. Asia Pacific VEGF Antibody Sales by Country (2027-2032) & (Kg) Table 57. South America, Middle East and Africa VEGF Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Kg) Table 58. South America, Middle East and Africa VEGF Antibody Sales by Country (2021-2026) & (Kg) Table 59. South America, Middle East and Africa VEGF Antibody Sales by Country (2027-2032) & (Kg) Table 60. Global VEGF Antibody Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global VEGF Antibody Revenue by Region (2021-2026) & (US$ Million) Table 62. Global VEGF Antibody Revenue by Region (2027-2032) & (US$ Million) Table 63. Global VEGF Antibody Revenue Market Share by Region (2021-2026) Table 64. Global VEGF Antibody Revenue Market Share by Region (2027-2032) Table 65. Abcam Company Information Table 66. Abcam Business Overview Table 67. Abcam VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Abcam VEGF Antibody Product Portfolio Table 69. Abcam Recent Development Table 70. Abnova Company Information Table 71. Abnova Business Overview Table 72. Abnova VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Abnova VEGF Antibody Product Portfolio Table 74. Abnova Recent Development Table 75. Absolute Antibody Company Information Table 76. Absolute Antibody Business Overview Table 77. Absolute Antibody VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Absolute Antibody VEGF Antibody Product Portfolio Table 79. Absolute Antibody Recent Development Table 80. Agrisera Company Information Table 81. Agrisera Business Overview Table 82. Agrisera VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Agrisera VEGF Antibody Product Portfolio Table 84. Agrisera Recent Development Table 85. BioLegend Company Information Table 86. BioLegend Business Overview Table 87. BioLegend VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. BioLegend VEGF Antibody Product Portfolio Table 89. BioLegend Recent Development Table 90. Bio-Rad Company Information Table 91. Bio-Rad Business Overview Table 92. Bio-Rad VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Bio-Rad VEGF Antibody Product Portfolio Table 94. Bio-Rad Recent Development Table 95. Bon Opus Biosciences Company Information Table 96. Bon Opus Biosciences Business Overview Table 97. Bon Opus Biosciences VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Bon Opus Biosciences VEGF Antibody Product Portfolio Table 99. Bon Opus Biosciences Recent Development Table 100. Creative Biomart Company Information Table 101. Creative Biomart Business Overview Table 102. Creative Biomart VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Creative Biomart VEGF Antibody Product Portfolio Table 104. Creative Biomart Recent Development Table 105. Enzo Life Sciences Company Information Table 106. Enzo Life Sciences Business Overview Table 107. Enzo Life Sciences VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Enzo Life Sciences VEGF Antibody Product Portfolio Table 109. Enzo Life Sciences Recent Development Table 110. ImmunoStar Company Information Table 111. ImmunoStar Business Overview Table 112. ImmunoStar VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. ImmunoStar VEGF Antibody Product Portfolio Table 114. ImmunoStar Recent Development Table 115. LifeSpan Biosciences Company Information Table 116. LifeSpan Biosciences Business Overview Table 117. LifeSpan Biosciences VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. LifeSpan Biosciences VEGF Antibody Product Portfolio Table 119. LifeSpan Biosciences Recent Development Table 120. MilliporeSigma Company Information Table 121. MilliporeSigma Business Overview Table 122. MilliporeSigma VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. MilliporeSigma VEGF Antibody Product Portfolio Table 124. MilliporeSigma Recent Development Table 125. Novus Biologicals Company Information Table 126. Novus Biologicals Business Overview Table 127. Novus Biologicals VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Novus Biologicals VEGF Antibody Product Portfolio Table 129. Novus Biologicals Recent Development Table 130. OriGene Company Information Table 131. OriGene Business Overview Table 132. OriGene VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. OriGene VEGF Antibody Product Portfolio Table 134. OriGene Recent Development Table 135. ProMab Company Information Table 136. ProMab Business Overview Table 137. ProMab VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. ProMab VEGF Antibody Product Portfolio Table 139. ProMab Recent Development Table 140. R&D Systems Company Information Table 141. R&D Systems Business Overview Table 142. R&D Systems VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. R&D Systems VEGF Antibody Product Portfolio Table 144. R&D Systems Recent Development Table 145. Rockland Immunochemicals Company Information Table 146. Rockland Immunochemicals Business Overview Table 147. Rockland Immunochemicals VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 148. Rockland Immunochemicals VEGF Antibody Product Portfolio Table 149. Rockland Immunochemicals Recent Development Table 150. Santa Cruz Biotechnology Company Information Table 151. Santa Cruz Biotechnology Business Overview Table 152. Santa Cruz Biotechnology VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 153. Santa Cruz Biotechnology VEGF Antibody Product Portfolio Table 154. Santa Cruz Biotechnology Recent Development Table 155. Sino Biological Company Information Table 156. Sino Biological Business Overview Table 157. Sino Biological VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 158. Sino Biological VEGF Antibody Product Portfolio Table 159. Sino Biological Recent Development Table 160. US Biological Company Information Table 161. US Biological Business Overview Table 162. US Biological VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 163. US Biological VEGF Antibody Product Portfolio Table 164. US Biological Recent Development Table 165. Boster Company Information Table 166. Boster Business Overview Table 167. Boster VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 168. Boster VEGF Antibody Product Portfolio Table 169. Boster Recent Development Table 170. Thermo Fisher Company Information Table 171. Thermo Fisher Business Overview Table 172. Thermo Fisher VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 173. Thermo Fisher VEGF Antibody Product Portfolio Table 174. Thermo Fisher Recent Development Table 175. Key Raw Materials Table 176. Raw Materials Key Suppliers Table 177. VEGF Antibody Distributors List Table 178. VEGF Antibody Customers List Table 179. Research Programs/Design for This Report Table 180. Authors List of This Report Table 181. Secondary Sources Table 182. Primary Sources List of Figures Figure 1. VEGF Antibody Product Image Figure 2. Global VEGF Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global VEGF Antibody Market Size (2021-2032) & (US$ Million) Figure 4. Global VEGF Antibody Sales (2021-2032) & (Kg) Figure 5. Global VEGF Antibody Average Price (US$/g) & (2021-2032) Figure 6. Global Top 5 and 10 VEGF Antibody Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Rabbit Image Figure 9. Mouse Image Figure 10. Goat Image Figure 11. Others Image Figure 12. Global VEGF Antibody Sales by Type (2021 VS 2025 VS 2032) & (Kg) Figure 13. Global VEGF Antibody Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global VEGF Antibody Sales Market Share by Type (2021-2032) Figure 15. Global VEGF Antibody Revenue by Type (2021 VS 2025 VS 2032) & (Kg) Figure 16. Global VEGF Antibody Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global VEGF Antibody Revenue Market Share by Type (2021-2032) Figure 18. Laboratory Image Figure 19. Hospital Image Figure 20. Others Image Figure 21. Global VEGF Antibody Sales by Application (2021 VS 2025 VS 2032) & (Kg) Figure 22. Global VEGF Antibody Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global VEGF Antibody Sales Market Share by Application (2021-2032) Figure 24. Global VEGF Antibody Revenue by Application (2021 VS 2025 VS 2032) & (Kg) Figure 25. Global VEGF Antibody Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global VEGF Antibody Revenue Market Share by Application (2021-2032) Figure 27. North America VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 28. North America VEGF Antibody Sales Market Share by Country (2021-2032) Figure 29. U.S. VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 30. Canada VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 31. Mexico VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 32. Europe VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 33. Europe VEGF Antibody Sales Market Share by Country (2021-2032) Figure 34. Germany VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 35. France VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 36. U.K. VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 37. Italy VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 38. Netherlands VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 39. Asia Pacific VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 40. Asia Pacific VEGF Antibody Sales Market Share by Country (2021-2032) Figure 41. China VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 42. Japan VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 43. South Korea VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 44. Southeast Asia VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 45. India VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 46. Australia VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 47. South America, Middle East and Africa VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 48. South America, Middle East and Africa VEGF Antibody Sales Market Share by Country (2021-2032) Figure 49. Brazil VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 50. South Africa VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 51. Saudi Arabia VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 52. Turkey VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 53. Argentina VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 54. UAE VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 55. Egypt VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 56. Chile VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg) Figure 57. Global VEGF Antibody Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global VEGF Antibody Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America VEGF Antibody Revenue (2021-2032) & (US$ Million) Figure 60. North America VEGF Antibody Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe VEGF Antibody Revenue (2021-2032) & (US$ Million) Figure 62. Europe VEGF Antibody Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific VEGF Antibody Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific VEGF Antibody Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa VEGF Antibody Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa VEGF Antibody Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. VEGF Antibody Value Chain Figure 68. Manufacturing Cost Structure Figure 69. VEGF Antibody Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Rabbit
  • Mouse
  • Goat
  • Others
Applications
  • Laboratory
  • Hospital
  • Others
Companies covered
  • Abcam
  • Abnova
  • Absolute Antibody
  • Agrisera
  • BioLegend
  • Bio-Rad
  • Bon Opus Biosciences
  • Creative Biomart
  • Enzo Life Sciences
  • ImmunoStar
  • LifeSpan Biosciences
  • MilliporeSigma
  • Novus Biologicals
  • OriGene
  • ProMab
  • R&D Systems
  • Rockland Immunochemicals
  • Santa Cruz Biotechnology
  • Sino Biological
  • US Biological
  • Boster
  • Thermo Fisher

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global VEGF Antibody Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global VEGF Antibody Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global VEGF Antibody Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global VEGF Antibody Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global VEGF Antibody Market Dynamics
  1. 2.1 VEGF Antibody Industry Trends
  2. 2.2 VEGF Antibody Industry Drivers
  3. 2.3 VEGF Antibody Industry Opportunities and Challenges
  4. 2.4 VEGF Antibody Industry Restraints
3 VEGF Antibody Market by Manufacturers
  1. 3.1 Global VEGF Antibody Revenue by Manufacturers (2021-2026)
  2. 3.2 Global VEGF Antibody Sales by Manufacturers (2021-2026)
  3. 3.3 Global VEGF Antibody Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global VEGF Antibody Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global VEGF Antibody Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global VEGF Antibody Manufacturers, Product Type & Application
  7. 3.7 Global VEGF Antibody Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global VEGF Antibody Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 VEGF Antibody Players Market Share by Revenue in 2025
  11. 3.8.3 2025 VEGF Antibody Tier 1, Tier 2, and Tier 3
4 VEGF Antibody Market by Type
  1. 4.1 VEGF Antibody Type Introduction
  2. 4.1.1 Rabbit
  3. 4.1.2 Mouse
  4. 4.1.3 Goat
  5. 4.1.4 Others
  6. 4.2 Global VEGF Antibody Sales by Type
  7. 4.2.1 Global VEGF Antibody Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global VEGF Antibody Sales by Type (2021-2032)
  9. 4.2.3 Global VEGF Antibody Sales Market Share by Type (2021-2032)
  10. 4.3 Global VEGF Antibody Revenue by Type
  11. 4.3.1 Global VEGF Antibody Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global VEGF Antibody Revenue by Type (2021-2032)
  13. 4.3.3 Global VEGF Antibody Revenue Market Share by Type (2021-2032)
5 VEGF Antibody Market by Application
  1. 5.1 VEGF Antibody Application Introduction
  2. 5.1.1 Laboratory
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global VEGF Antibody Sales by Application
  6. 5.2.1 Global VEGF Antibody Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global VEGF Antibody Sales by Application (2021-2032)
  8. 5.2.3 Global VEGF Antibody Sales Market Share by Application (2021-2032)
  9. 5.3 Global VEGF Antibody Revenue by Application
  10. 5.3.1 Global VEGF Antibody Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global VEGF Antibody Revenue by Application (2021-2032)
  12. 5.3.3 Global VEGF Antibody Revenue Market Share by Application (2021-2032)
6 Global VEGF Antibody Sales by Region
  1. 6.1 Global VEGF Antibody Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global VEGF Antibody Sales by Region (2021-2032)
  3. 6.2.1 Global VEGF Antibody Sales by Region (2021-2026)
  4. 6.2.2 Global VEGF Antibody Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America VEGF Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America VEGF Antibody Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe VEGF Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe VEGF Antibody Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific VEGF Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific VEGF Antibody Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa VEGF Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa VEGF Antibody Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global VEGF Antibody Revenue by Region
  1. 7.1 Global VEGF Antibody Revenue by Region
  2. 7.1.1 Global VEGF Antibody Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global VEGF Antibody Revenue by Region (2021-2026)
  4. 7.1.3 Global VEGF Antibody Revenue by Region (2027-2032)
  5. 7.1.4 Global VEGF Antibody Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America VEGF Antibody Revenue (2021-2032)
  8. 7.2.2 North America VEGF Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe VEGF Antibody Revenue (2021-2032)
  11. 7.3.2 Europe VEGF Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific VEGF Antibody Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific VEGF Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa VEGF Antibody Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa VEGF Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Abcam
  2. 8.1.1 Abcam Company Information
  3. 8.1.2 Abcam Business Overview
  4. 8.1.3 Abcam VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abcam VEGF Antibody Product Portfolio
  6. 8.1.5 Abcam Recent Developments
  7. 8.2 Abnova
  8. 8.2.1 Abnova Company Information
  9. 8.2.2 Abnova Business Overview
  10. 8.2.3 Abnova VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Abnova VEGF Antibody Product Portfolio
  12. 8.2.5 Abnova Recent Developments
  13. 8.3 Absolute Antibody
  14. 8.3.1 Absolute Antibody Company Information
  15. 8.3.2 Absolute Antibody Business Overview
  16. 8.3.3 Absolute Antibody VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Absolute Antibody VEGF Antibody Product Portfolio
  18. 8.3.5 Absolute Antibody Recent Developments
  19. 8.4 Agrisera
  20. 8.4.1 Agrisera Company Information
  21. 8.4.2 Agrisera Business Overview
  22. 8.4.3 Agrisera VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Agrisera VEGF Antibody Product Portfolio
  24. 8.4.5 Agrisera Recent Developments
  25. 8.5 BioLegend
  26. 8.5.1 BioLegend Company Information
  27. 8.5.2 BioLegend Business Overview
  28. 8.5.3 BioLegend VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 BioLegend VEGF Antibody Product Portfolio
  30. 8.5.5 BioLegend Recent Developments
  31. 8.6 Bio-Rad
  32. 8.6.1 Bio-Rad Company Information
  33. 8.6.2 Bio-Rad Business Overview
  34. 8.6.3 Bio-Rad VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bio-Rad VEGF Antibody Product Portfolio
  36. 8.6.5 Bio-Rad Recent Developments
  37. 8.7 Bon Opus Biosciences
  38. 8.7.1 Bon Opus Biosciences Company Information
  39. 8.7.2 Bon Opus Biosciences Business Overview
  40. 8.7.3 Bon Opus Biosciences VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Bon Opus Biosciences VEGF Antibody Product Portfolio
  42. 8.7.5 Bon Opus Biosciences Recent Developments
  43. 8.8 Creative Biomart
  44. 8.8.1 Creative Biomart Company Information
  45. 8.8.2 Creative Biomart Business Overview
  46. 8.8.3 Creative Biomart VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Creative Biomart VEGF Antibody Product Portfolio
  48. 8.8.5 Creative Biomart Recent Developments
  49. 8.9 Enzo Life Sciences
  50. 8.9.1 Enzo Life Sciences Company Information
  51. 8.9.2 Enzo Life Sciences Business Overview
  52. 8.9.3 Enzo Life Sciences VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Enzo Life Sciences VEGF Antibody Product Portfolio
  54. 8.9.5 Enzo Life Sciences Recent Developments
  55. 8.10 ImmunoStar
  56. 8.10.1 ImmunoStar Company Information
  57. 8.10.2 ImmunoStar Business Overview
  58. 8.10.3 ImmunoStar VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 ImmunoStar VEGF Antibody Product Portfolio
  60. 8.10.5 ImmunoStar Recent Developments
  61. 8.11 LifeSpan Biosciences
  62. 8.11.1 LifeSpan Biosciences Company Information
  63. 8.11.2 LifeSpan Biosciences Business Overview
  64. 8.11.3 LifeSpan Biosciences VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 LifeSpan Biosciences VEGF Antibody Product Portfolio
  66. 8.11.5 LifeSpan Biosciences Recent Developments
  67. 8.12 MilliporeSigma
  68. 8.12.1 MilliporeSigma Company Information
  69. 8.12.2 MilliporeSigma Business Overview
  70. 8.12.3 MilliporeSigma VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 MilliporeSigma VEGF Antibody Product Portfolio
  72. 8.12.5 MilliporeSigma Recent Developments
  73. 8.13 Novus Biologicals
  74. 8.13.1 Novus Biologicals Company Information
  75. 8.13.2 Novus Biologicals Business Overview
  76. 8.13.3 Novus Biologicals VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Novus Biologicals VEGF Antibody Product Portfolio
  78. 8.13.5 Novus Biologicals Recent Developments
  79. 8.14 OriGene
  80. 8.14.1 OriGene Company Information
  81. 8.14.2 OriGene Business Overview
  82. 8.14.3 OriGene VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 OriGene VEGF Antibody Product Portfolio
  84. 8.14.5 OriGene Recent Developments
  85. 8.15 ProMab
  86. 8.15.1 ProMab Company Information
  87. 8.15.2 ProMab Business Overview
  88. 8.15.3 ProMab VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 ProMab VEGF Antibody Product Portfolio
  90. 8.15.5 ProMab Recent Developments
  91. 8.16 R&D Systems
  92. 8.16.1 R&D Systems Company Information
  93. 8.16.2 R&D Systems Business Overview
  94. 8.16.3 R&D Systems VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 R&D Systems VEGF Antibody Product Portfolio
  96. 8.16.5 R&D Systems Recent Developments
  97. 8.17 Rockland Immunochemicals
  98. 8.17.1 Rockland Immunochemicals Company Information
  99. 8.17.2 Rockland Immunochemicals Business Overview
  100. 8.17.3 Rockland Immunochemicals VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Rockland Immunochemicals VEGF Antibody Product Portfolio
  102. 8.17.5 Rockland Immunochemicals Recent Developments
  103. 8.18 Santa Cruz Biotechnology
  104. 8.18.1 Santa Cruz Biotechnology Company Information
  105. 8.18.2 Santa Cruz Biotechnology Business Overview
  106. 8.18.3 Santa Cruz Biotechnology VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Santa Cruz Biotechnology VEGF Antibody Product Portfolio
  108. 8.18.5 Santa Cruz Biotechnology Recent Developments
  109. 8.19 Sino Biological
  110. 8.19.1 Sino Biological Company Information
  111. 8.19.2 Sino Biological Business Overview
  112. 8.19.3 Sino Biological VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Sino Biological VEGF Antibody Product Portfolio
  114. 8.19.5 Sino Biological Recent Developments
  115. 8.20 US Biological
  116. 8.20.1 US Biological Company Information
  117. 8.20.2 US Biological Business Overview
  118. 8.20.3 US Biological VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 US Biological VEGF Antibody Product Portfolio
  120. 8.20.5 US Biological Recent Developments
  121. 8.21 Boster
  122. 8.21.1 Boster Company Information
  123. 8.21.2 Boster Business Overview
  124. 8.21.3 Boster VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Boster VEGF Antibody Product Portfolio
  126. 8.21.5 Boster Recent Developments
  127. 8.22 Thermo Fisher
  128. 8.22.1 Thermo Fisher Company Information
  129. 8.22.2 Thermo Fisher Business Overview
  130. 8.22.3 Thermo Fisher VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Thermo Fisher VEGF Antibody Product Portfolio
  132. 8.22.5 Thermo Fisher Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 VEGF Antibody Value Chain Analysis
  2. 9.1.1 VEGF Antibody Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 VEGF Antibody Production Mode & Process
  6. 9.2 VEGF Antibody Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 VEGF Antibody Distributors
  9. 9.2.3 VEGF Antibody Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst